01 2Diovan
02 5Diovan Group
03 2Entresto
04 2Exforge
05 4Exforge Group
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 980
2019 Revenue in Millions : 1,025
Growth (%) : -4
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 1,003
2019 Revenue in Millions : 1,064
Growth (%) : -6
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 2,497
2019 Revenue in Millions : 1,726
Growth (%) : 45
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 773
2020 Revenue in Millions : 1,003
Growth (%) : -23
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 901
2020 Revenue in Millions : 980
Growth (%) : -8
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 652
2021 Revenue in Millions : 773
Growth (%) : -16
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 743
2021 Revenue in Millions : 901
Growth (%) : -18
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 713
2022 Revenue in Millions : 743
Growth (%) : -4
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 613
2022 Revenue in Millions : 652
Growth (%) : -6
Hydrochlorothiazide and Valsartan
Main Therapeutic Indication : Antihypertensives
Currency : USD
2014 Revenue in Millions : -33.50%
2013 Revenue in Millions :
Growth (%) :
LOOKING FOR A SUPPLIER?